Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Diagonal Therapeutics General Information
In preclinical models of HHT, Diagonal's agonist antibodies have shown the ability to prevent and reverse the formation of pathological vascular malformations
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
DIAG723
Pre-clinicalKey Partnerships
Diagonal Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Jan 8, 2026 | $125.0M | Completed | Preclinical |
To view Diagonal Therapeutics's complete valuation and funding history, request access »